Pharma News

People who wear reusable contact lenses are nearly four times as likely as those wearing daily disposables to develop a rare sight-threatening eye infection, finds a study led by UCL and Moorfields researchers.

Two new UC Davis Health studies explored how differences in skin composition may lead to dermatological conditions, such as psoriasis and atopic dermatitis.

“Skin does not have a uniform composition throughout the body,” said Emanual Maverakis, professor of dermatology, molecular medical microbiology at UC Davis and senior author on both studies. “Different skin characteristics at different body sites may affect the skin’s susceptibility to certain diseases.”

A new mechanism that slows down and may even prevent the natural ageing of immune cells – one of the nine hallmarks of ageing – has been identified by an international team led by UCL scientists.

Published in Nature Cell Biology, researchers say the discovery in-vitro (cells) and validated in mice was ‘unexpected’ and believe harnessing the mechanism could extend the life of the immune system, allowing people to live healthier and longer, and would also have clinical utility for diseases such as cancer and dementia.

Government constitutes a committee on affordable medicines and health products to address the issues of pharma industries giving temptation for prescribing medicines.

The committee is chaired by Niti ayog and contains five members which includes, Chief Economic Adviser, Ministry of Finance; Secretary, Department of Health Research; Vice-Chairperson, NLEM Joint; Secretary, Department of Industrial Policy & Promotion; and Director General of Health Services, Ministry of Health & Family Welfare.

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product loncastuximab tesirine (Zynlonta), intended for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

The applicant for this medicinal product is ADC Therapeutics (NL) B.V.

it may be the most baffling quirk of COVID: What manifests as minor, flu-like symptoms in some individuals spirals into severe disease, disability, or even death in others. A new paper published in Nature may explain the genetic underpinnings of this dichotomy.

Shilpa medicare gets CDSCO approval for Tranexamic Acid Spray, Hemostatic Spray. The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.

This two-day event was held on September 15th and 16th.It was a uniquely planned event, where the focus was on understanding how organisations can build an apt strategy for achieving manufacturing excellence and using digital and automation as tools for modernising.
The conference ensured continuous engagement of the audience & speakers through various discussions in the form of Case-Study solving, Panel Discussion and group discussions to understand and create a viable Business Strategy for exponential growth.

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART  leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.